Teva Pharmaceutical Industries (TEVA) Debt Ratio (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Debt Ratio for 18 consecutive years, with 0.42 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Debt Ratio fell 3.02% year-over-year to 0.42; the trailing twelve-month figure through Jun 2026 stood at 0.42 (down 3.02% YoY), and the FY2025 full-year result was 0.41, down 8.79% from the prior year.
• Debt Ratio held at 0.42 in Q2 2026 per TEVA's latest filing, from 0.42 in the prior quarter.
• Across five years, Debt Ratio topped out at 0.49 in Q1 2022 and bottomed at 0.41 in Q4 2025.
• Historically, Debt Ratio has averaged 0.45 across 5 years, with a median of 0.46 in 2023.
• The sharpest annual moves came in 2023 and 2025: Debt Ratio slipped 0.21% in 2023, then retreated 8.79% in 2025.
• Over 5 years, Debt Ratio stood at 0.48 in 2022, then dropped by 5.36% to 0.46 in 2023, then retreated by 0.87% to 0.45 in 2024, then declined by 8.79% to 0.41 in 2025, then gained by 0.93% to 0.42 in 2026.
• According to Business Quant data, Debt Ratio over the past three periods registered 0.42, 0.42, and 0.41 for Q2 2026, Q1 2026, and Q4 2025 respectively.